Incyte (INCY) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is INCY's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Incyte Corporation (INCY) Presents at UBS Global Biopharma Conference 2026 Transcript…

Incyte secures EC approval for Povofortay, the first once-daily oral HS treatment in the EU, opening a new growth opportunity backed by strong clinical results.…

Incyte Corporation (INCY) Presents at Jefferies Global Healthcare Conference 2026 Transcript…

Incyte says EU approves oral treatment for chronic skin disease…

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa.…

Eurizon Capital SGR S.p.A. decreased its position in Incyte Corporation (NASDAQ: INCY) by 13.0% during a recent quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm own…

Incyte NASDAQ: INCY is preparing for a transition away from its JAKAFI business, with Chief Executive Officer Bill Meury pointing to product launches and a pipeline of late-stage drug candidates as potential sources of g…

Incyte Corporation (INCY) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript…

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has entered into a clinical collaboration agreement with Incyte (Nasdaq:INCY) f…

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte is proud to announce that the University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute have been selected as the recipients of the 2026 Inc…

Compass Financial Management LLC bought a new position in shares of Incyte Corporation (NASDAQ: INCY) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Com…

Aware Super Pty Ltd as trustee of Aware Super lowered its position in Incyte Corporation (NASDAQ: INCY) by 4.5% during a recent quarter, according to the company in its most recent Form 13F filing with the SEC. The firm …

Pre-Market Stock Futures: Futures are trading lower this Friday, with the Nasdaq down almost 2.…

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.…

I upgraded Incyte to Hold, with a fair value of $112.19 per share, now just 4% below the market price. ESMO Phase 1 data for KRAS G12D and TGFβR2×PD-1 support higher approval probabilities. Q3 net sales rose 14% year-ove…

Incyte's Q3 2026 revenues beat estimates as strong product demand lifts sales 14%, prompting higher 2026 guidance despite acquisition-driven losses.…

Incyte Corporation (INCY) Q3 2026 Earnings Call Transcript…

Incyte NASDAQ: INCY reported third-quarter revenue of $1.56 billion, up 14% from a year earlier, as growth in its dermatology and hematology-oncology products helped offset a more modest increase in Jakafi sales. The com…

Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the…

Incyte (INCY) came out with a quarterly loss of $3.6 per share versus the Zacks Consensus Estimate of a loss of $3.99. This compares to earnings of $2.26 per share a year ago.…

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates.…

Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript…

Incyte NASDAQ: INCY presented updated clinical data and development plans for two experimental solid-tumor programs at ESMO in Madrid: INCA33890, a TGFβR2-by-PD-1 bispecific antibody known as “'890,” and INCB161734, a KR…

INCY and GMAB team up to evaluate a three-drug combination for first-line treatment of KRAS G12D-mutated metastatic colorectal cancer.…

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ESMO26--Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026.…

COPENHAGEN, Denmark & WILMINGTON, Del.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab's investigational IgG1-bispecif…

WILMINGTON, Del. & COPENHAGEN, Denmark--(BUSINESS WIRE)---- $INCY--Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer.…

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ESMO2026--Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026.…

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte today announced eight winners of the 2026 MPN Heroes® annual recognition program. The program, now in its 14th year, pays tribute to individuals whose contributions to patient ca…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 10. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

